Wegovy and Zepbound prices are dropping, but steady access to the weight-loss drugs remains a challenge

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

The medications still amount to around $500 per month for those without insurance—out of reach for many patients. And even for people with insurance, coverage remains uneven.

“The medications should be available, the question is at what price and can people sustain that,” said Matt Maciejewski, a Duke University professor who studies obesity treatment coverage.